• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab.

作者信息

Trefond Ludovic, Chasset Francois, Jachiet Marie, Livideanu Cristina, Barba Thomas, Faguer Stanislas, Henry Julien, Richard-Colmant Gaelle, Ferreira-Maldent Nicole, Roque Sandrine, Monteiro Ruben, Chevalier Kevin, Lanteri Aurelia, Lazaro Estibaliz, Scherlinger Marc, Belhomme Nicolas, Richez Christophe, Cazalets Claire, Sailler Laurent, Abdallah Nassim Ait, de La Rochefoucauld Jeanne, Campagne Julien, Audemard Alexandra, Moulinet Thomas, Abisror Noemie, Costedoat-Chalumeau Nathalie, Lesort Cecile, Bessis Didier, Kottler Diane, Saint-Pastou Terrier Cecile, Jeandel Pierre-Yves, Lechtman Sarah, Grolleau Chloé, Hadjadj Jérome, Pereira Bruno, Smets Perrine, André Marc, Bouaziz Jean-David, Mathian Alexis, Amoura Zahir

机构信息

Service de Médecine Interne, Centre de Référence pour les Maladies auto immunes et auto inflammatoires Systémiques Rares d'Auvergne, CHU Gabriel-Montpied, Inserm U1071, M2iSH, USC-INRA 1382, Clermont-Ferrand, France, Université Clermont Auvergne, Clermont-Ferrand, France

Sorbonne Université, Faculté de Médecine, APHP, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France, Paris, Île-de-France, France.

出版信息

RMD Open. 2025 Jan 4;11(1):e005076. doi: 10.1136/rmdopen-2024-005076.

DOI:10.1136/rmdopen-2024-005076
PMID:39756824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11749790/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/823a/11749790/7f61a2e03f81/rmdopen-11-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/823a/11749790/7f61a2e03f81/rmdopen-11-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/823a/11749790/7f61a2e03f81/rmdopen-11-1-g001.jpg

相似文献

1
Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab.伐昔洛韦在接受阿尼芬净单抗治疗的患者中预防带状疱疹的疗效。
RMD Open. 2025 Jan 4;11(1):e005076. doi: 10.1136/rmdopen-2024-005076.
2
Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.阿尼鲁单抗用于狼疮的干扰素抑制：对导致美国食品药品监督管理局批准的证据的批判性评估。
ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14.
3
Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.生物制剂治疗系统性红斑狼疮或活动性狼疮肾炎及感染并发症发生率。来自大型临床试验的证据。
Front Immunol. 2022 Sep 23;13:999704. doi: 10.3389/fimmu.2022.999704. eCollection 2022.
4
Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials.阿尼鲁单抗治疗活动性系统性红斑狼疮：一项随机对照试验的荟萃分析。
Z Rheumatol. 2021 Dec;80(10):988-994. doi: 10.1007/s00393-020-00928-7. Epub 2020 Nov 20.
5
[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.[翻译文章] 阿尼鲁单抗在系统性红斑狼疮、皮肤型红斑狼疮及其他自身免疫性皮肤病中的应用
Actas Dermosifiliogr. 2025 Jan;116(1):T55-T67. doi: 10.1016/j.ad.2024.10.008. Epub 2024 Oct 9.
6
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.阿尼鲁单抗，一种针对 I 型干扰素受体亚单位 1 的单克隆抗体，用于治疗系统性红斑狼疮：临床试验概述。
Mod Rheumatol. 2021 Jan;31(1):1-12. doi: 10.1080/14397595.2020.1812201. Epub 2020 Sep 17.
7
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.阿尼鲁单抗：首个在欧盟获批的生物制剂，不限于疾病活动度高的患者，用于治疗中重度系统性红斑狼疮。
Expert Rev Clin Immunol. 2024 Jan-Jun;20(1):21-30. doi: 10.1080/1744666X.2023.2268284. Epub 2024 Jan 8.
8
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.阿尼鲁单抗治疗活动性系统性红斑狼疮的试验。
N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
9
The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis.日本系统性红斑狼疮患者使用阿尼鲁单抗的长期安全性和耐受性：TULIP-LTE 亚组分析。
Mod Rheumatol. 2024 Jul 6;34(4):720-731. doi: 10.1093/mr/road092.
10
Valaciclovir: a review of its use in the management of herpes zoster.伐昔洛韦：用于带状疱疹治疗的综述
Drugs. 2000 Jun;59(6):1317-40. doi: 10.2165/00003495-200059060-00009.

引用本文的文献

1
Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS.阿尼鲁单抗在系统性红斑狼疮中的上市后安全信号：一项基于FAERS的药物警戒研究
BMC Rheumatol. 2025 Jul 21;9(1):90. doi: 10.1186/s41927-025-00545-4.
2
Advances in the treatment of systemic lupus erythematosus.系统性红斑狼疮治疗的进展
Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0.

本文引用的文献

1
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.一项评估阿尼鲁单抗在活跃系统性红斑狼疮患者中长期安全性和耐受性的随机、安慰剂对照 III 期扩展试验。
Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11.
2
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.存在能中和 IFN-α 的自身抗体的系统性红斑狼疮患者，其疾病活动度较低，但 COVID-19 和带状疱疹的重症风险较高。
Ann Rheum Dis. 2022 Dec;81(12):1695-1703. doi: 10.1136/ard-2022-222549. Epub 2022 Aug 16.
3
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
阿尼鲁单抗治疗活动期系统性红斑狼疮患者的安全性特征：II 期和 III 期临床试验的综合分析。
Lupus Sci Med. 2021 Feb;8(1). doi: 10.1136/lupus-2020-000464.
4
The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis.成人系统性红斑狼疮患者感染风险：系统评价和荟萃分析。
Rheumatology (Oxford). 2021 Jan 5;60(1):60-72. doi: 10.1093/rheumatology/keaa478.